富含胞嘧啶的脱氧寡核苷酸对免疫反应的负调节作用
|
摘要
近年的研究表明,具有特定序列的单链脱氧寡核苷酸(ODN)具有免疫负调节作用,可能通过干预免疫系统或免疫细胞的异常活化,成为治疗自身免疫病、超敏反应和Toll样受体活化相关性疾病的药物。这类ODN被称为抑制性ODN,为人王合成的、长约几十个核苷酸的单链DNA分子。有研究表明,抑制性ODN可以抑制含CpG基序ODN(CpG ODN)的免疫刺激作用,也可能抑制LPS诱导的免疫反应等,且多为富含鸟嘌吟(G)的ODN。
根据哺乳动物线粒体DNA的序列特点以及对可能具有免疫负调节活性ODN的结构特性认识,我们设计了13条单链脱氧寡核苷酸,分别命名为MT00～12。然后,利用生物学活性方法对MT00～12是否能抑制免疫激活剂诱导免疫细胞产生抗病毒物质进行了筛选,发现富含胞嘧啶的MT01表现出较强的抑制活性。进一步研究显示:1)MT01不仅能抑制TLR9激动剂CpG ODN诱导的免疫反应,也能抑制灭活的DNA病毒、TLR7激动剂咪喹莫特或灭活的RNA病毒诱导的免疫反应,但对TLR4诱导的免疫反应则无抑制作用;2)MT01对SLE病人血清刺激的免疫反应也具有明显的抑制作用:3)MT01的结构,尤其富含胞嘧啶区域与其生物学活性直接相关,构效关系研究显示其免疫负调节活性可能是序列依赖性的:4)MT01在小鼠体内能明显抑制CpG ODN对乙肝表面抗原特异性抗体诱生的增强作用,但对乙肝表面抗原刺激抗体产生无抑制作用,说明MT01可能只对过强的免疫反应具有抑制作用;5)MT01可抑制小鼠B细胞活化,这提示其对抗原特异性抗体产生的抑制作用可能是通过抑制B细胞活化而实现的。
综上,一种富含胞嘧啶的单链脱氧寡核苷酸(MT01)具有选择性免疫负调节活性,可能具有治疗自身免疫病或TLR7/9活化相关性疾病的潜在应用价值。
In homeostatic conditions,immune activation is protective in a host. Functioning as pattern recognition receptors,Toll-like receptors(TLRs),which are broadly distributed on immune cells,initiate innate immune activation in response to conserved microbial molecules including lipopolysaccharide(LPS),flagellin, unmethylated CpG DNA,viral RNA,etc,and result in the production of inflammatory cytokines,activation of DC and B cells and the induction of specific, adaptive immunity to the pathogen.However,if the innate immune system through the TLR dysregulated,the activation may implicated in various genetic diseases and a number of conditions including susceptibility to infections,lung diseases, autoimmune diseases such as systemic lupus erythematosus(SLE),inflammatory bowel disease(IBD) and atherosclerosis.Recent studies demonstrate that the use of suppressive oligodeoxynucleotide,an artificial single-stranded DNA molecule with length of dozens nucleotides,may potentially have significant clinical utility in those immune activation associated disease.
In this study,among the ODN designated as MTODN we desigened,we describe here the identification of a candidate suppressive oligodeoxynucleotide (MT01).MT01 was subsequently analysed in detail in terms of inhibitory potency. kinetics,and mode of action.It was found that MT01 could down-regulate TLR7/9-dependent IFN production and proliferation in cultured human peripheral blood monouclear cells(PBMCs) and murine spleen cells,induced by CpG oligodeoxynucleotides(CpG ODN).imiquimod,inactivated herpessimplexvirus-1 (HSV-1),inactivated influenza A virus Puerto-Rico-Stamm 8(PR8)、influenza A virus A/Fort Monmouth/1/1947 H1N1 strain(FM1) and sera from SLE patients.Moreover. MT01 was examined for its functionality in a hepatitis B surface antigen(HBsAg) plus CpG ODN immunized mouse model.
1 Designing and screening of MT ODN
1.1 Designing of MTODN
To develop immunosuppressive oligodeoxynucleotides with novel sequences as potential candidates for treating immune responses-associated diseases such as autoimmune diseases,serials of ODNs were designed and screened in our lab.It has been reported that there are certain DNA in mammalian genome which negatively regulate immune activations.According to sequence of mitochondrial DNA and basic sequence feature of suppressive ODN,we designed 13 sequences of MT ODN (MT00～12).Among them,repeat units were from 2 to 9 nucleotides.
1.2 Screening of MT ODN
The inhibitory effects of the MT ODNs were tested in a VSV protection bioassay for determining IFN production from human PBMCs induced by CpG 2216 (1μg/mL),a typical A-type CpG ODN.The result showed that the supernatant of human PBMCs induced by CpG 2216 could protect Veto E6 cells from VSV challenge and MT01(8μg/mL) displayed significant inhibition but other MT ODNs couldn't.When used alone,none of MTODNs could stimulate human PBMCs to produced IFN evidently.Compared with all of other MTODNs,MT01 possessed the feature of C-rich sequence.
1.3 Evaluating supernatant of human PBMCs
It was necessary to know whether the cytotoxicity of remaining MT01 in the supernatant of human PBMCs lead to the inhibition of MT01.Vero cells were cultured with the supernatant for 48 h and they all growed as well.Then we detect the culture supernatant of each group by 3%agarose gel electrophoresis.The result showed that there weren't remaining ODN in the supernatant of Medium group、MT01 group、CpG 2216 group and CpG 2216+MT01 group.It is implied that the cell death was due to the inhibition of MT01 on CpG 2216 induced immune activation.
1.4 Confirming the inhibitory effect of MT01
Human PBMCs were cultured with CpG 2216(1μg/mL) and/or MT01(0.25, 0.5,1,2,4,8 and 16μg/mL) for 48 h or 72 h.The results showed that the inhibition of MT01 was enhanced by the increasing concentration.The time point of 48 h was chosen for the following experiments.
2 Effect of MT01 on TLR9 induced human PBMC activation
As a common artificial TLR9 agnist,CpG ODN could stimulate pDC to produce a large amount of IFN-α(known as A-type CpG ODN,e.g.CpG 2216) and stimulate B cell proliferation(known as B-type CpG ODN,e.g.CpG 2006,CpG BW006).And C-type CpG ODN possess both A-and B-type characteristics. Meanwhile,we took heat inactivated DNA virus-herpessimplexvirus-1(HSV-1) as natural TLR9 agnist to investigate the inhibitory effect of MT01.
2.1 Effect of MT01 on CpG ODN induced antiviral activity of human PBMCs
Human PBMCs were cultured with CpG 2216(1μg/mL) and/or MT01(0.25、0.5、1、2、4、8 16 and 32μg/mL) for 48 h.The doses of MT01 that began to act its suppressive effect were 1μg/mL,when the dose of MT01 increased the inhibitory effect enhanced.MT01 at 4μg/mL reached suppressive flat when human PBMCs were stimulated by CpG 2216 and CpG BW006.MT01 at 8μg/ml was selected as the optimal dosage in latter vitro experiments for testing its inhibitory effect with consistency.
2.2 Effect of MT01 on human PBMC proliferation induced by CpG ODN
Human PBMCs were cultured with CpG 2006(1μg/mL),CpG BW006,CpG C274 and/or MT01(0.25、0.5、1、2、4、8 16 and 32μg/mL) for 48 h.From the result of VSV protection bioassay,MT01 was found to inhibit CpG ODN induced human PBMC proliferation in a dose-dependent manner.While used alone.MT01 couldn't stimulate human PBMC proliferation.
As the parallel control,MS19 couldn't inhibit CpG ODN-induced IFN production and proliferation of human PBMCs.indicating that MT01 certainly possessed inhibitory role on immune responses without any toxicity.
2.3 Kinetics of MT01 on CpG ODN induced IFN production of human PBMCs
To exclude the possibility whether the MT01 displayed inhibition was due to its extracellular interference with CpG ODN,the kinetics of the inhibition of MT01 was studied when using CpG 2216 as the stimulatory CpG ODN.MT01(8μg/mL) was added to human PBMCs at various times(0.25h,0.5h,1h,2h,3h,4h,5h,6h) after or before the addition of CpG 2216(1μg/mL).The result showed that significant inhibition was observed when MT01 were co-administered with CpG 2216 or added before CpG 2216(p＜0.01).MT01 was noticeably inhibitory even when added less then 2 h after addition of CpG 2216(p＜0.01) and could also inhibit CpG 2216 induced IFN production when added at the time point of 3 h and 6 h after addition of CpG 2216(p＜0.05).It was indicating that the inhibition of MT01 on TLR9 activation was consistent and was not because of the extracellular interference with CpG ODN.
2.4 Structure-function analysis of MT01
Structurally,MT01 was entirely composed of three repeats of a C-rich motif.To determine whether the repeat numbers of the motif contributed to the suppressive effect,ODNs that contained one and two of the motif were synthesized,named MT01a and MT01b respectively.We used VSV protection bioassay and proliferation assay to compare the inhibitory effect of them.The result showed that the inhibitory effect of MT01 a was much weaker than MT01b,while that of MT01 b was also weak than MT01.The inhibitory effect of MT01 on CpG ODN induced IFN production and proliferation was at the maximum so we didn't observe the inhibitory effect of ODNs with four or more motifs.
2.5 Effect of MT01 on antiviral activity of human PBMCs induced by heat inactive DNA virus
Act as natural TLR9 agonist.DNA virus could also result in acute or chronic diseases.Human PBMCs were cultured with heat inactive HSV-1 and/or MT01(8 g/mL) for 3.6,12,24 h.The result of VSV protection assay showed that MT01 could inhibit heat inactive HSV-1 induced antiviral activity of human PBMCs once the antiviral activity induced by the heat inactive HSV-1 was detected.
3 Effect of MT01 on TLR7 induced human PBMC activation
It was reported that TLR7 activation could be a therapeutic target in autoimmune diseases.It was necessary to know whether MTO1 could inhibit the immune activation though TLR7.
3.1 Effect of MT01 on antiviral activity of human PBMCs induced by IMQ Human PBMCs were cultured with IMQ(0.25μg/mL) and/or MT01(8μg/mL) for 48 h.The result of VSV protection bioassay showed that MT01 inhibited imiquimod(p＜0.01) induced IFN production.
3.2 Effect of MT01 on antiviral activity of human PBMCs induced by heat inactive RNA virus
RNA virus,natural TLR7 agonist,could induce human PBMCs to produce IFN. Human PBMCs were cultured with heat inactive influenza A virus Puerto-Rico-Stamm 8(PR8),influenza A virus A/Fort Monmouth/1/1947 H1N1 strain (FM1) and/or MT01(8μg/mL) for 48 h.The antiviral activity was detected by VSV protection assay.The result of showed that supernatant of human PBMCs induced by heat inactive PR8 or FM1 could protect Veto cells against VSV attack,and MT01 could inhibit the antiviral activity induced by the heat inactive RNA virus.
4 Effect of MT01 on antiviral activity induced by serum from SLE patients
Human PBMCs were treated with serum from 16 SLE patients for 48 h. Compared with normal serum group,the supernatant of SLE-1,SLE-9,SLE-14 and SLE-15 could protect the Vero E6 against VSV attacking.Then human PBMCs were cultured with serum from the above 4 SLE patients or in the present of MT01 for 48 h. In VSV protection assay,MT01 remarkably inhibited the antiviral activity induced by serum from SLE patients.The data indicated that MT01 could inhibit endogenous ligands of SLE patients,providing a therapeutic point for SLE or other autoimmune diseases.
5 Suppressive effect of MT01 on cultured mouse cells
In the above experiments used human PBMCs as the cell model.MT01 displayed its inhibitory effect on TLR7/9 activation.Some ODNs were granted in a species-specific manner.To determine whether MT01 was also species dependent and the feasibility of evaluating its in vivo effect in mice,we established two platforms for detecting mouse reactive inhibitory ODN.
5.1 Effect of MT01 on antiviral activity of mouse splenocytes induced by CpG ODN
After screening the concentration(0、0.25、0.5、1、2、4、8、16 and 32μg/mL) and the incubation time(3、6、12、24、48、72 and 96 h) of CpG 2216,the dilution of the supernatant induced by CpG 2216,the concentration(1,2,4,8,16,32 or 64μg/mL) of A151,the method established was as followed:mouse splenocytes(cell density 5×10~6·mL~(-1)) were cultured with 2μg/mL CpG 2216 and/or 16μg/mL suppressive ODN for 24 h.The supernatants were collected and added to L929 cells by 1:4 dilution.After 18 h incubation,the cells were cultured with VSV for 48 h and A578 was detected to screen suppressive ODN.Using CpG 2216 as the stimulator and A151 as the positive suppressive ODN,the conditions of screening experiment were established successfully and could be used for identifying mouse reactive suppressive ODN.It was demonstrated that MT01could inhibit the antiviral activity of mouse splenocytes induced by CpG 2216 by this method(P＜0.01),and the inhibitory effect was not due to cytotoxicity by 3%agarose gel electrophoresis.
5.2 Effect of MT01 on proliferation of spleen cells induced by CpG ODN
Next,we established a MTT method to detect mouse splenocytes proliferation. The method established was as followed:mouse splenocytes(cell density 5×10~6·mL~(-1)) were cultured with 4μg/mL CpG 2006 and/or 16gg/mL suppressive ODN for 24 h and then the cell proliferation was detected with routine MTT.Using this method, MT01was detected to inhibit mouse splenocyte proliferation induced by CpG 2006(P＜0.01).
Mouse splenocytes were cultured with MT01(8μg/mL) and/or CpG ODN(B type CpG ODN,CpG 2006 and CpG BW006)(C type CpG ODN,CpG C274)(1μg/mL) for 48 h to confirm above results.The result of ~3H-thymidine incorporation assay also showed that MT01 could inhibit mouse splenocytes proliferation by above CpG ODN(P＜0.01).
5.3 Effect of MT01 on antiviral activity of mouse splenocytes induced by heat inactive virus
To investigate whether MT01 could inhibit immune activation by natural TLR7/9 agonist in mouse splenocyte model,mouse splenocytes were cultured with heat inactive virus(HSV-1 or FM1) and/or MT01 for 48 h.The result showed that the antiviral activity of mouse splenocytes induced by HSV-1 and FM1MT01 could be inhibited by MT01(P＜0.01),but not by MS19.
5.4 Effect of MT01 on proliferation of mouse splenocyte induced by LPS
We chose LPS as TLR4 agonist to investigate whether MT01 could inhibit LPS induced proliferation.The result of ~3H-thymidine incorporation assay showed neither MT01 nor MS19 could inhibit LPS induced proliferation of mouse splenocytes,indicating that MT01 couldn't inhibit activation indeced by TLR4 agonist.
6 Effect of MT01 on antibody production in mice and its mechanism
From above in vitro experiments,it was demonstrated that MT01 could work in both human PBMC model and mouse splenocyte model.Next,we investigate the in vivo effect of MT01.
6.1 Effect of MT01 on anti-HBs production in HBsAg immunized mice
Mice immunized with HBsAg or HBsAg plus CpG BW006were used as an animal model to test whether MT01 could inhibit antibody production in vivo.Female BALB/c mice(n=6) were immunized with HBV vaccine(containing 1μg HBsAg/mouse) or plus CpG BW006(5μg/mouse) on days 1,29 by injection the agents into the tibialis posterior muscle,and were injected with MT01(50μg/mouse) on day 0,7,14,21,28,35,42 and 49 to investigate whether MT01 could inhibit the production of anti-HBs antibodies in mice.The mice were bled on days -2,13,20,27, 34,41,48,and 55 to collect sera for detecting anti-HBs antibodies by ELISA.MT01, in mice immunized with HBV vaccine plus CpG BW006.inhibited the production of anti-HBs antibodies on day 35,42.49 and 56(p＜0.01).But in mice immunized with HBV vaccine alone.MT01 didn't inhibit the production,indicating that MT01 inhibited only the CpG ODN enhanced antibody response.
6.2 The possible mechanism of MT01 mediated inhibition on CpG ODN induced antibody production
To determine the cells on which the MT01 exerted its inhibition on antibody production induced by antigens,splenocytes from BALB/c mouse were stimulated by CpG BW006 in the presence of MT01 or MS19 as a negative control ODN.Cells were then doubly stained with PE-labeled anti-CD19 mAb and FITC-labeled anti-CD69 mAb at 12 h,with PE-labeled anti-CD19 mAb and FITC-labeled anti-CD80 mAb at 72 h and followed by the analysis on a FACS Calibur.The result showed that CpG BW006 obviously up-regulate CD69 and CD80 expression of the gated CD19~+ cells.The up-regulation of the CD69 was almost completely inhibited by MT01,and the up-regulation of the CD80 was inhibited by half.The results demonstrate that the inhibition of MT01 on antibody production could be through the TLR9 pathways in B cells.
To sum up,the C-rich oligodeoxynucleotide designated as MT01 designed by our laboratory could inhibit the immune activation of human PBMC or mouse splenocyte induced by various stimuli,and could inhibit over-production of antibody in mice.As a novel class of immunosuppressive ODN,MT01 could be of therapeutic use in immune activation associated diseases.
根据哺乳动物线粒体DNA的序列特点以及对可能具有免疫负调节活性ODN的结构特性认识,我们设计了13条单链脱氧寡核苷酸,分别命名为MT00～12。然后,利用生物学活性方法对MT00～12是否能抑制免疫激活剂诱导免疫细胞产生抗病毒物质进行了筛选,发现富含胞嘧啶的MT01表现出较强的抑制活性。进一步研究显示:1)MT01不仅能抑制TLR9激动剂CpG ODN诱导的免疫反应,也能抑制灭活的DNA病毒、TLR7激动剂咪喹莫特或灭活的RNA病毒诱导的免疫反应,但对TLR4诱导的免疫反应则无抑制作用;2)MT01对SLE病人血清刺激的免疫反应也具有明显的抑制作用:3)MT01的结构,尤其富含胞嘧啶区域与其生物学活性直接相关,构效关系研究显示其免疫负调节活性可能是序列依赖性的:4)MT01在小鼠体内能明显抑制CpG ODN对乙肝表面抗原特异性抗体诱生的增强作用,但对乙肝表面抗原刺激抗体产生无抑制作用,说明MT01可能只对过强的免疫反应具有抑制作用;5)MT01可抑制小鼠B细胞活化,这提示其对抗原特异性抗体产生的抑制作用可能是通过抑制B细胞活化而实现的。
综上,一种富含胞嘧啶的单链脱氧寡核苷酸(MT01)具有选择性免疫负调节活性,可能具有治疗自身免疫病或TLR7/9活化相关性疾病的潜在应用价值。
In homeostatic conditions,immune activation is protective in a host. Functioning as pattern recognition receptors,Toll-like receptors(TLRs),which are broadly distributed on immune cells,initiate innate immune activation in response to conserved microbial molecules including lipopolysaccharide(LPS),flagellin, unmethylated CpG DNA,viral RNA,etc,and result in the production of inflammatory cytokines,activation of DC and B cells and the induction of specific, adaptive immunity to the pathogen.However,if the innate immune system through the TLR dysregulated,the activation may implicated in various genetic diseases and a number of conditions including susceptibility to infections,lung diseases, autoimmune diseases such as systemic lupus erythematosus(SLE),inflammatory bowel disease(IBD) and atherosclerosis.Recent studies demonstrate that the use of suppressive oligodeoxynucleotide,an artificial single-stranded DNA molecule with length of dozens nucleotides,may potentially have significant clinical utility in those immune activation associated disease.
In this study,among the ODN designated as MTODN we desigened,we describe here the identification of a candidate suppressive oligodeoxynucleotide (MT01).MT01 was subsequently analysed in detail in terms of inhibitory potency. kinetics,and mode of action.It was found that MT01 could down-regulate TLR7/9-dependent IFN production and proliferation in cultured human peripheral blood monouclear cells(PBMCs) and murine spleen cells,induced by CpG oligodeoxynucleotides(CpG ODN).imiquimod,inactivated herpessimplexvirus-1 (HSV-1),inactivated influenza A virus Puerto-Rico-Stamm 8(PR8)、influenza A virus A/Fort Monmouth/1/1947 H1N1 strain(FM1) and sera from SLE patients.Moreover. MT01 was examined for its functionality in a hepatitis B surface antigen(HBsAg) plus CpG ODN immunized mouse model.
1 Designing and screening of MT ODN
1.1 Designing of MTODN
To develop immunosuppressive oligodeoxynucleotides with novel sequences as potential candidates for treating immune responses-associated diseases such as autoimmune diseases,serials of ODNs were designed and screened in our lab.It has been reported that there are certain DNA in mammalian genome which negatively regulate immune activations.According to sequence of mitochondrial DNA and basic sequence feature of suppressive ODN,we designed 13 sequences of MT ODN (MT00～12).Among them,repeat units were from 2 to 9 nucleotides.
1.2 Screening of MT ODN
The inhibitory effects of the MT ODNs were tested in a VSV protection bioassay for determining IFN production from human PBMCs induced by CpG 2216 (1μg/mL),a typical A-type CpG ODN.The result showed that the supernatant of human PBMCs induced by CpG 2216 could protect Veto E6 cells from VSV challenge and MT01(8μg/mL) displayed significant inhibition but other MT ODNs couldn't.When used alone,none of MTODNs could stimulate human PBMCs to produced IFN evidently.Compared with all of other MTODNs,MT01 possessed the feature of C-rich sequence.
1.3 Evaluating supernatant of human PBMCs
It was necessary to know whether the cytotoxicity of remaining MT01 in the supernatant of human PBMCs lead to the inhibition of MT01.Vero cells were cultured with the supernatant for 48 h and they all growed as well.Then we detect the culture supernatant of each group by 3%agarose gel electrophoresis.The result showed that there weren't remaining ODN in the supernatant of Medium group、MT01 group、CpG 2216 group and CpG 2216+MT01 group.It is implied that the cell death was due to the inhibition of MT01 on CpG 2216 induced immune activation.
1.4 Confirming the inhibitory effect of MT01
Human PBMCs were cultured with CpG 2216(1μg/mL) and/or MT01(0.25, 0.5,1,2,4,8 and 16μg/mL) for 48 h or 72 h.The results showed that the inhibition of MT01 was enhanced by the increasing concentration.The time point of 48 h was chosen for the following experiments.
2 Effect of MT01 on TLR9 induced human PBMC activation
As a common artificial TLR9 agnist,CpG ODN could stimulate pDC to produce a large amount of IFN-α(known as A-type CpG ODN,e.g.CpG 2216) and stimulate B cell proliferation(known as B-type CpG ODN,e.g.CpG 2006,CpG BW006).And C-type CpG ODN possess both A-and B-type characteristics. Meanwhile,we took heat inactivated DNA virus-herpessimplexvirus-1(HSV-1) as natural TLR9 agnist to investigate the inhibitory effect of MT01.
2.1 Effect of MT01 on CpG ODN induced antiviral activity of human PBMCs
Human PBMCs were cultured with CpG 2216(1μg/mL) and/or MT01(0.25、0.5、1、2、4、8 16 and 32μg/mL) for 48 h.The doses of MT01 that began to act its suppressive effect were 1μg/mL,when the dose of MT01 increased the inhibitory effect enhanced.MT01 at 4μg/mL reached suppressive flat when human PBMCs were stimulated by CpG 2216 and CpG BW006.MT01 at 8μg/ml was selected as the optimal dosage in latter vitro experiments for testing its inhibitory effect with consistency.
2.2 Effect of MT01 on human PBMC proliferation induced by CpG ODN
Human PBMCs were cultured with CpG 2006(1μg/mL),CpG BW006,CpG C274 and/or MT01(0.25、0.5、1、2、4、8 16 and 32μg/mL) for 48 h.From the result of VSV protection bioassay,MT01 was found to inhibit CpG ODN induced human PBMC proliferation in a dose-dependent manner.While used alone.MT01 couldn't stimulate human PBMC proliferation.
As the parallel control,MS19 couldn't inhibit CpG ODN-induced IFN production and proliferation of human PBMCs.indicating that MT01 certainly possessed inhibitory role on immune responses without any toxicity.
2.3 Kinetics of MT01 on CpG ODN induced IFN production of human PBMCs
To exclude the possibility whether the MT01 displayed inhibition was due to its extracellular interference with CpG ODN,the kinetics of the inhibition of MT01 was studied when using CpG 2216 as the stimulatory CpG ODN.MT01(8μg/mL) was added to human PBMCs at various times(0.25h,0.5h,1h,2h,3h,4h,5h,6h) after or before the addition of CpG 2216(1μg/mL).The result showed that significant inhibition was observed when MT01 were co-administered with CpG 2216 or added before CpG 2216(p＜0.01).MT01 was noticeably inhibitory even when added less then 2 h after addition of CpG 2216(p＜0.01) and could also inhibit CpG 2216 induced IFN production when added at the time point of 3 h and 6 h after addition of CpG 2216(p＜0.05).It was indicating that the inhibition of MT01 on TLR9 activation was consistent and was not because of the extracellular interference with CpG ODN.
2.4 Structure-function analysis of MT01
Structurally,MT01 was entirely composed of three repeats of a C-rich motif.To determine whether the repeat numbers of the motif contributed to the suppressive effect,ODNs that contained one and two of the motif were synthesized,named MT01a and MT01b respectively.We used VSV protection bioassay and proliferation assay to compare the inhibitory effect of them.The result showed that the inhibitory effect of MT01 a was much weaker than MT01b,while that of MT01 b was also weak than MT01.The inhibitory effect of MT01 on CpG ODN induced IFN production and proliferation was at the maximum so we didn't observe the inhibitory effect of ODNs with four or more motifs.
2.5 Effect of MT01 on antiviral activity of human PBMCs induced by heat inactive DNA virus
Act as natural TLR9 agonist.DNA virus could also result in acute or chronic diseases.Human PBMCs were cultured with heat inactive HSV-1 and/or MT01(8 g/mL) for 3.6,12,24 h.The result of VSV protection assay showed that MT01 could inhibit heat inactive HSV-1 induced antiviral activity of human PBMCs once the antiviral activity induced by the heat inactive HSV-1 was detected.
3 Effect of MT01 on TLR7 induced human PBMC activation
It was reported that TLR7 activation could be a therapeutic target in autoimmune diseases.It was necessary to know whether MTO1 could inhibit the immune activation though TLR7.
3.1 Effect of MT01 on antiviral activity of human PBMCs induced by IMQ Human PBMCs were cultured with IMQ(0.25μg/mL) and/or MT01(8μg/mL) for 48 h.The result of VSV protection bioassay showed that MT01 inhibited imiquimod(p＜0.01) induced IFN production.
3.2 Effect of MT01 on antiviral activity of human PBMCs induced by heat inactive RNA virus
RNA virus,natural TLR7 agonist,could induce human PBMCs to produce IFN. Human PBMCs were cultured with heat inactive influenza A virus Puerto-Rico-Stamm 8(PR8),influenza A virus A/Fort Monmouth/1/1947 H1N1 strain (FM1) and/or MT01(8μg/mL) for 48 h.The antiviral activity was detected by VSV protection assay.The result of showed that supernatant of human PBMCs induced by heat inactive PR8 or FM1 could protect Veto cells against VSV attack,and MT01 could inhibit the antiviral activity induced by the heat inactive RNA virus.
4 Effect of MT01 on antiviral activity induced by serum from SLE patients
Human PBMCs were treated with serum from 16 SLE patients for 48 h. Compared with normal serum group,the supernatant of SLE-1,SLE-9,SLE-14 and SLE-15 could protect the Vero E6 against VSV attacking.Then human PBMCs were cultured with serum from the above 4 SLE patients or in the present of MT01 for 48 h. In VSV protection assay,MT01 remarkably inhibited the antiviral activity induced by serum from SLE patients.The data indicated that MT01 could inhibit endogenous ligands of SLE patients,providing a therapeutic point for SLE or other autoimmune diseases.
5 Suppressive effect of MT01 on cultured mouse cells
In the above experiments used human PBMCs as the cell model.MT01 displayed its inhibitory effect on TLR7/9 activation.Some ODNs were granted in a species-specific manner.To determine whether MT01 was also species dependent and the feasibility of evaluating its in vivo effect in mice,we established two platforms for detecting mouse reactive inhibitory ODN.
5.1 Effect of MT01 on antiviral activity of mouse splenocytes induced by CpG ODN
After screening the concentration(0、0.25、0.5、1、2、4、8、16 and 32μg/mL) and the incubation time(3、6、12、24、48、72 and 96 h) of CpG 2216,the dilution of the supernatant induced by CpG 2216,the concentration(1,2,4,8,16,32 or 64μg/mL) of A151,the method established was as followed:mouse splenocytes(cell density 5×10~6·mL~(-1)) were cultured with 2μg/mL CpG 2216 and/or 16μg/mL suppressive ODN for 24 h.The supernatants were collected and added to L929 cells by 1:4 dilution.After 18 h incubation,the cells were cultured with VSV for 48 h and A578 was detected to screen suppressive ODN.Using CpG 2216 as the stimulator and A151 as the positive suppressive ODN,the conditions of screening experiment were established successfully and could be used for identifying mouse reactive suppressive ODN.It was demonstrated that MT01could inhibit the antiviral activity of mouse splenocytes induced by CpG 2216 by this method(P＜0.01),and the inhibitory effect was not due to cytotoxicity by 3%agarose gel electrophoresis.
5.2 Effect of MT01 on proliferation of spleen cells induced by CpG ODN
Next,we established a MTT method to detect mouse splenocytes proliferation. The method established was as followed:mouse splenocytes(cell density 5×10~6·mL~(-1)) were cultured with 4μg/mL CpG 2006 and/or 16gg/mL suppressive ODN for 24 h and then the cell proliferation was detected with routine MTT.Using this method, MT01was detected to inhibit mouse splenocyte proliferation induced by CpG 2006(P＜0.01).
Mouse splenocytes were cultured with MT01(8μg/mL) and/or CpG ODN(B type CpG ODN,CpG 2006 and CpG BW006)(C type CpG ODN,CpG C274)(1μg/mL) for 48 h to confirm above results.The result of ~3H-thymidine incorporation assay also showed that MT01 could inhibit mouse splenocytes proliferation by above CpG ODN(P＜0.01).
5.3 Effect of MT01 on antiviral activity of mouse splenocytes induced by heat inactive virus
To investigate whether MT01 could inhibit immune activation by natural TLR7/9 agonist in mouse splenocyte model,mouse splenocytes were cultured with heat inactive virus(HSV-1 or FM1) and/or MT01 for 48 h.The result showed that the antiviral activity of mouse splenocytes induced by HSV-1 and FM1MT01 could be inhibited by MT01(P＜0.01),but not by MS19.
5.4 Effect of MT01 on proliferation of mouse splenocyte induced by LPS
We chose LPS as TLR4 agonist to investigate whether MT01 could inhibit LPS induced proliferation.The result of ~3H-thymidine incorporation assay showed neither MT01 nor MS19 could inhibit LPS induced proliferation of mouse splenocytes,indicating that MT01 couldn't inhibit activation indeced by TLR4 agonist.
6 Effect of MT01 on antibody production in mice and its mechanism
From above in vitro experiments,it was demonstrated that MT01 could work in both human PBMC model and mouse splenocyte model.Next,we investigate the in vivo effect of MT01.
6.1 Effect of MT01 on anti-HBs production in HBsAg immunized mice
Mice immunized with HBsAg or HBsAg plus CpG BW006were used as an animal model to test whether MT01 could inhibit antibody production in vivo.Female BALB/c mice(n=6) were immunized with HBV vaccine(containing 1μg HBsAg/mouse) or plus CpG BW006(5μg/mouse) on days 1,29 by injection the agents into the tibialis posterior muscle,and were injected with MT01(50μg/mouse) on day 0,7,14,21,28,35,42 and 49 to investigate whether MT01 could inhibit the production of anti-HBs antibodies in mice.The mice were bled on days -2,13,20,27, 34,41,48,and 55 to collect sera for detecting anti-HBs antibodies by ELISA.MT01, in mice immunized with HBV vaccine plus CpG BW006.inhibited the production of anti-HBs antibodies on day 35,42.49 and 56(p＜0.01).But in mice immunized with HBV vaccine alone.MT01 didn't inhibit the production,indicating that MT01 inhibited only the CpG ODN enhanced antibody response.
6.2 The possible mechanism of MT01 mediated inhibition on CpG ODN induced antibody production
To determine the cells on which the MT01 exerted its inhibition on antibody production induced by antigens,splenocytes from BALB/c mouse were stimulated by CpG BW006 in the presence of MT01 or MS19 as a negative control ODN.Cells were then doubly stained with PE-labeled anti-CD19 mAb and FITC-labeled anti-CD69 mAb at 12 h,with PE-labeled anti-CD19 mAb and FITC-labeled anti-CD80 mAb at 72 h and followed by the analysis on a FACS Calibur.The result showed that CpG BW006 obviously up-regulate CD69 and CD80 expression of the gated CD19~+ cells.The up-regulation of the CD69 was almost completely inhibited by MT01,and the up-regulation of the CD80 was inhibited by half.The results demonstrate that the inhibition of MT01 on antibody production could be through the TLR9 pathways in B cells.
To sum up,the C-rich oligodeoxynucleotide designated as MT01 designed by our laboratory could inhibit the immune activation of human PBMC or mouse splenocyte induced by various stimuli,and could inhibit over-production of antibody in mice.As a novel class of immunosuppressive ODN,MT01 could be of therapeutic use in immune activation associated diseases.
引文
[1] Akira S. Mammalian Toll-like receptors[J]. Current Opinion in Immunology, 2003, 1(15): 5-11.
[2] Akira S, K Takeda, T Kaisho. Toll-like receptors: critical proteins linking innate and acquired immunity[J]. Nature Immunology, 2001, 8(2): 675-680.
[3] Baccala R, K Hoebe, D H Kono et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity[J]. Nat Med, 2007, 5(13): 543-551.
[4] Baechler E C, P K Gregersen, T W Behrens. The emerging role of interferon in human systemic lupus erythematosus[J]. Curr Opin Immunol, 2004, 6(16): 801-807.
[5] Barrat F J, T Meeker, J H Chan et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms[J]. Eur J Immunol, 2007, 12(37): 3582-3586.
[6] Barrat F J, T Meeker, J Gregorio et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus[J]. J Exp Med, 2005, 8(202): 1131-1139.
[7] Bhakdi S. Pathogenesis of atherosclerosis: infectious versus immune pathogenesis. A new concept[J]. Herz, 2000, 2(25): 84-86.
[8] Blackwell S E, A M Krieg. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha[J]. J Immunol, 2003, 8(170): 4061-4068.
[9] Blanco P, A K Palucka, M Gill et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus[J]. Science, 2001, 5546(294): 1540-1543.
[10] Carusa G M Caffo, G Raudino et al. Antisense Oligonucleotides as Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas[J]. Recent Pat CNS Drug Discov, 2009.
[11] Cheng X, Y Chen, J J Xie et al. Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance[J]. J Mol Cell Cardiol, 2008, 2(45): 168-175.
[12] Christensen S R. M Kashgarian. L Alexopoulou et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus[J]. J Exp Med, 2005. 2(202): 321-331.
[13] Cong Z, M Wan. X Wu et al. A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells[J]. FEMS Immunol Med Microbiol. 2007. 1(51): 26-34.
[14] Cooper C L. H L Davis. M L Morris et al. CPG 7909. an immunostimulatory TLR9 agonist oligodeoxynucleotide. as adjuvant to Engerix-B (R) HBV vaccine in healthy adults: A double-blind phase I/II study[J]. Journal of Clinical Immunology, 2004a, 6(24): 693-701.
[15] Cooper C L, H L Davis, M L Morris et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine[J]. Vaccine, 2004b, 23-24(22): 3136-3143.
[16] Dong L, S Ito, K J Ishii et al. Suppressive oligonucleotides protect against collagen-induced arthritis in mice[J]. Arthritis Rheum, 2004, 5(50): 1686-1689.
[17] Dong L, S Ito, K J Ishii et al. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice[J]. Arthritis Rheum, 2005, 2(52): 651-658.
[18] Drexler S K, B M Foxwell. The role of Toll-like receptors in chronic inflammation[J]. Int J Biochem Cell Biol, 2009.
[19] Ehrenstein M R, E McSweeney, M Swane et al. Appearance of anti-DNA antibodies in patients treated with interferon-alpha[J]. Arthritis Rheum, 1993, 2(36): 279-280.
[20] Essakalli M, O Atouf, N Bennani et al. Toll-like receptors [J]. Pathologie Biologie, 2009, 5(57): 430-438.
[21] Finke D, M L Eloranta, L Ronnblom. Endogenous type I interferon inducers in autoimmune diseases[J]. Autoimmunity, 2009, 4(42): 349-352.
[22] Freytag L C, J D Clements. Mucosal adjuvants[J]. Vaccine, 2005, 15(23): 1804-1813.
[23] Fujimoto C, D M Klinman, G Shi et al. A suppressive oligodeoxynucleotide inhibits ocular inflammation[J]. Clin Exp Immunol. 2009, 3(156): 528-534.
[24] Funk J, T Langeland, E Schrumpf et al. Psoriasis induced by interferon-alpha[J]. Br J Dermatol, 1991, 5(125): 463-465.
[25] Geary R S, S P Henry. L R Grillone. Fomivirsen: clinical pharmacology and potential drug interactions[J]. Clin Pharmacokinet. 2002, 4(41): 255-260.
[26] Gilliet M, C Conrad, M Geiges et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors[J]. Arch Dermatol. 2004, 12(140): 1490-1495.
[27] Grammer A C, P E Lipsky. B cell abnormalities in systemic lupus erythematosus[J]. Arthritis Res Ther. 2003, 5 Suppl 4): S22-27.
[28] Grillone L R. R Lanz. Fomivirsen [J]. Drugs Today (Barc), 2001. 4(37): 245-255.
[29] Gursel I, M Gursel. H Yamada et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation[J]. J Immunol. 2003.3(171): 1393-1400.
[30] Hacker H. H Mischak. T Miethke et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation [J]. EMBO J, 1998. 21(17): 6230-6240.
[31] Halpern M D. D S Pisetsky. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers[.I]. Immunopharmacology. 1995. 1(29): 47-52.
[32]Hemmi H,O Takeuchi,T Kawai et al.A Toll-like receptor recognizes bacterial DNA[J].Nature,2000,6813(408):740-745.
[33]Ho P P,P Fontoura,P J Ruiz et al.An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems[J].J Immunol,2003,9(171):4920-4926.
[34]Hochrein H,B Schlatter,M O'Keeffe et al.Herpes simplex virus type-1induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways[J].Proc Natl Acad Sci U S A,2004,31(101):11416-11421.
[35]Honda K,T Taniguchi.IRFs:master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors[J].Nat Rev Immunol,2006,9(6):644-658.
[36]Hu D,X Su,R Sun et al.Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells[J].Mol Immunol,2009.
[37]Iwamura C,T Nakayama.Toll-like receptors in the respiratory system:Their roles in inflammation[J].Current Allergy and Asthma Reports,2008,1(8):7-13.
[38]Janssens S,R Beyaert.Role of Toll-like receptors in pathogen recognition[J].Clin Microbiol Rev,2003,4(16):637-646.
[39]Jin M S,J O Lee.Ligand Recognition by the Toll-like Receptor Family[J].Animal Cells and Systems,2009,1(13):1-8.
[40]Kawai T,S Akira.TLR signaling[J].Seminars in Immunology,2007,1(19):24-32.
[41]Kawai T,S Akira.The roles of TLRs,RLRs and NLRs in pathogen recognition[J].Int Immunol,2009,4(21):317-337.
[42]Ketikoglou I,S Karatapanis,I Elefsiniotis et al.Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B[J].Eur J Dermatol,2005,2(15):107-109.
[43]Kline J N,A M Krieg.Toll-Like Receptor 9 Activation with CpG Oligodeoxynucleotides for Asthma Therapy[J].Drug News & Perspectives,2008,8(21):434-439.
[44]Krieg A M.CpG DNA:a pathogenic factor in systemic lupus erythematosus?[J].J Clin Immunol,1995a,6(15):284-292.
[45]Krieg A M.Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides[J].Biochimica Et Biophysica Acta-Gene Structure and Expression.1999.1(1489):107-116.
[46]Krieg A M.Development of TLR9 agonists for cancer therapy[J].J Clin Invest,2007a,5(117):1184-1194.
[47]Krieg A M.Toll-like receptor 9(TLR9) agonists in the treatment of cancer[J].Oncogene,2008,2(27):161-167.
[48]Krieg A M,J Vollmer.Toll-like receptors 7,8.and 9:linking innate immunity to autoimmunity[J].Immunol Rev,2007b,220):251-269.
[49]Krieg A M,T Wu.R Weeratna et al.Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs[J].Proc Natl Acad Sci U S A,1998,21(95):12631-12636.
[50]Krieg A M,A K Yi,S Matson et al.CpG motifs in bacterial DNA trigger direct B-cell activation[J].Nature,1995b,6522(374):546-549.
[51]Krug A,G D Luker,W Barchet et al.Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9[J].Blood,2004,4(103):1433-1437.
[52]Krug A,S Rothenfusser,V Hornung et al.Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells[J].Eur J Immunol,2001,7(31):2154-2163.
[53]Krug A,S Rothenfusser,S Selinger et al.CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells[J].J Immunol,2003,7(170):3468-3477.
[54]Latz E,A Schoenemeyer,A Visintin et al.TLR9 signals after translocating from the ER to CpG DNA in the lysosome[J].Nat Immunol,2004,2(5):190-198.
[55]Liew F Y,D Xu,E K Brint et al.Negative regulation of toll-like receptor-mediated immune responses[J].Nat Rev Immunol,2005,6(5):446-458.
[56]Macfarlane D E,L Manzel.Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine,chloroquine,and structurally related compounds[J].J Immunol,1998,3(160):1122-1131.
[57]Mallat Z.Suppressive oligodeoxynucleotides inhibit atherosclerosis[J].J Mol Cell Cardiol,2008,2(45):156-158.
[58]Marshak-Rothstein A,I R Rifkin.Immunologically active autoantigens:the role of toll-like receptors in the development of chronic inflammatory disease[J].Annu Rev Immunol,2007,25):419-441.
[59]Martin D A,K B Elkon.Autoantibodies make a U-turn:the toll hypothesis for autoantibody specificity[J].J Exp Med,2005,11(202):1465-1469.
[60]Means T K,E Latz,F Hayashi et al.Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9[J].J Clin Invest,2005,2(115):407-417.
[61]Megyeri K.W C Au,I Rosztoczy et al.Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways[J].Mol Cell Biol,1995,4(15):2207-2218.
[62]Nakano H.M Yanagita.M D Gunn.CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells[J].J Exp Med.2001,8(194):1171-1178.
[63]Nakano S.S Morimoto.J Suzuki et al.Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus[J].Rheumatology(Oxford),2008,2(47):145-149.
[64]Paterson B M,B E Roberts.E L Kuff.Structural gene identification and mapping bv DNA-mRNA hybrid-arrested cell-free translation[J].Proc Natl Acad Sci U S A,1977.10(74):4370-4374.
[65]Patole P S,D Zecher,R D Pawar et al.G-rich DNA suppresses systemic lupus[J].J Am Soc Nephrol,2005,11(16):3273-3280.
[66]Peterson K S,J F Huang,J Zhu et al.Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli[J].J Clin Invest,2004,12(113):1722-1733.
[67]Pisetsky D S.The role of innate immunity in the induction of autoimmunity[J].Autoimmun Rev,2008,1(8):69-72.
[68]Pisetsky D S,C F Reich.Inhibition of murine macrophage IL-12 production by natural and synthetic DNA[J].Clin Immunol,2000,3(96):198-204.
[69]Ronnblom L,M L Eloranta,G V Alm.Role of natural interferon-alpha producing cells(plasmacytoid dendritic cells) in autoimmunity[J].Autoimmunity,2003,8(36):463-472.
[70]Ronnblom L E,G V Alm,K E Oberg.Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors[J].Ann Intern Med,1991,3(115):178-183.
[71]Ross R.Atherosclerosis is an inflammatory disease[J].Am Heart J,1999,5 Pt 2(138):S419-420.
[72]Salaun B,P Romero,S Lebecque.Toll-like receptors' two-edged sword:when immunity meets apoptosis[J].Eur J Immunol,2007,12(37):3311-3318.
[73]Santer D M,T Yoshio,S Minota et al.Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus[J].J Immunol,2009,2(182):1192-1201.
[74]Sobczak K,N Bangel-Ruland,J Semmler et al.[Antisense oligonucleotides for therapy of cystic fibrosis:Inhibition of sodium absorption mediated by ENaC in nasal epithelial cells.][J].HNO,2009.
[75]Stunz L L,P Lenert,D Peckham et al.Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells[J].Eur J Immunol,2002,5(32):1212-1222.
[76]Takeda K,S Akira.Toll-like receptors in innate immunity[J].Int Immunol,2005b,1(17):1-14.
[77]Takeda K,T Kaisho,S Akira.Toll-like receptors[J].Annual Review of Immunology,2003,21):335-376.
[78]Tokunaga T,H Yamamoto,S Shimada et al.Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG.I.Isolation,physicochemical characterization,and antitumor activity[J].J Natl Cancer Inst,1984,4(72):955-962.
[79]Trieu A,T L Roberts,J A Dunn et al.DNA motifs suppressing TLR9responses[J].Crit Rev Immunol,2006,6(26):527-544.
[80]Uematsu S.S Akira.The role of Toll-like receptors in immune disorders[J].Expert Opinion on Biological Therapy,2006.3(6):203-214.
[81]Uematsu S,S Akira.Toll-like receptor and innate immunity[J].Seikagaku,2007.8(79):769-776.
[82]Verthelyi D,K J Ishii.M Gursel et al.Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs[J].J Immunol. 2001, 4(166): 2372-2377.
[83] Vollmer J, A M Krieg. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists[J]. Adv Drug Deliv Rev, 2009, 3(61): 195-204.
[84] Vollmer J, R Weeratna, P Payette et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immuno stimulatory activities [J]. Eur J Immunol, 2004, 1(34): 251-262.
[85] Wiemann B, C O Starnes. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective [J]. Pharmacol Ther, 1994, 3(64): 529-564.
[86] Yamamoto S, E Kuramoto, S Shimada et al. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG[J]. Jpn J Cancer Res, 1988, 7(79): 866-873.
[87] Yao Y, L Richman, C Morehouse et al. Type I interferon: potential therapeutic target for psoriasis?[J]. PLoS One, 2008, 7(3): e2737.
[88] Zamecnik P C, M L Stephenson. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide [J]. Proc Natl Acad Sci U S A, 1978, 1(75): 280-284.
[89] Zhu F G, C F Reich. D S Pisetsky. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides[J]. J Leukoc Biol, 2002a, 6(72): 1154-1163.
[90] Zhu F G, C F Reich, D S Pisetsky. Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides[J]. J Leukoc Biol. 2002b, 4(71): 686-694.
[2] Akira S, K Takeda, T Kaisho. Toll-like receptors: critical proteins linking innate and acquired immunity[J]. Nature Immunology, 2001, 8(2): 675-680.
[3] Baccala R, K Hoebe, D H Kono et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity[J]. Nat Med, 2007, 5(13): 543-551.
[4] Baechler E C, P K Gregersen, T W Behrens. The emerging role of interferon in human systemic lupus erythematosus[J]. Curr Opin Immunol, 2004, 6(16): 801-807.
[5] Barrat F J, T Meeker, J H Chan et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms[J]. Eur J Immunol, 2007, 12(37): 3582-3586.
[6] Barrat F J, T Meeker, J Gregorio et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus[J]. J Exp Med, 2005, 8(202): 1131-1139.
[7] Bhakdi S. Pathogenesis of atherosclerosis: infectious versus immune pathogenesis. A new concept[J]. Herz, 2000, 2(25): 84-86.
[8] Blackwell S E, A M Krieg. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha[J]. J Immunol, 2003, 8(170): 4061-4068.
[9] Blanco P, A K Palucka, M Gill et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus[J]. Science, 2001, 5546(294): 1540-1543.
[10] Carusa G M Caffo, G Raudino et al. Antisense Oligonucleotides as Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas[J]. Recent Pat CNS Drug Discov, 2009.
[11] Cheng X, Y Chen, J J Xie et al. Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance[J]. J Mol Cell Cardiol, 2008, 2(45): 168-175.
[12] Christensen S R. M Kashgarian. L Alexopoulou et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus[J]. J Exp Med, 2005. 2(202): 321-331.
[13] Cong Z, M Wan. X Wu et al. A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells[J]. FEMS Immunol Med Microbiol. 2007. 1(51): 26-34.
[14] Cooper C L. H L Davis. M L Morris et al. CPG 7909. an immunostimulatory TLR9 agonist oligodeoxynucleotide. as adjuvant to Engerix-B (R) HBV vaccine in healthy adults: A double-blind phase I/II study[J]. Journal of Clinical Immunology, 2004a, 6(24): 693-701.
[15] Cooper C L, H L Davis, M L Morris et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine[J]. Vaccine, 2004b, 23-24(22): 3136-3143.
[16] Dong L, S Ito, K J Ishii et al. Suppressive oligonucleotides protect against collagen-induced arthritis in mice[J]. Arthritis Rheum, 2004, 5(50): 1686-1689.
[17] Dong L, S Ito, K J Ishii et al. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice[J]. Arthritis Rheum, 2005, 2(52): 651-658.
[18] Drexler S K, B M Foxwell. The role of Toll-like receptors in chronic inflammation[J]. Int J Biochem Cell Biol, 2009.
[19] Ehrenstein M R, E McSweeney, M Swane et al. Appearance of anti-DNA antibodies in patients treated with interferon-alpha[J]. Arthritis Rheum, 1993, 2(36): 279-280.
[20] Essakalli M, O Atouf, N Bennani et al. Toll-like receptors [J]. Pathologie Biologie, 2009, 5(57): 430-438.
[21] Finke D, M L Eloranta, L Ronnblom. Endogenous type I interferon inducers in autoimmune diseases[J]. Autoimmunity, 2009, 4(42): 349-352.
[22] Freytag L C, J D Clements. Mucosal adjuvants[J]. Vaccine, 2005, 15(23): 1804-1813.
[23] Fujimoto C, D M Klinman, G Shi et al. A suppressive oligodeoxynucleotide inhibits ocular inflammation[J]. Clin Exp Immunol. 2009, 3(156): 528-534.
[24] Funk J, T Langeland, E Schrumpf et al. Psoriasis induced by interferon-alpha[J]. Br J Dermatol, 1991, 5(125): 463-465.
[25] Geary R S, S P Henry. L R Grillone. Fomivirsen: clinical pharmacology and potential drug interactions[J]. Clin Pharmacokinet. 2002, 4(41): 255-260.
[26] Gilliet M, C Conrad, M Geiges et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors[J]. Arch Dermatol. 2004, 12(140): 1490-1495.
[27] Grammer A C, P E Lipsky. B cell abnormalities in systemic lupus erythematosus[J]. Arthritis Res Ther. 2003, 5 Suppl 4): S22-27.
[28] Grillone L R. R Lanz. Fomivirsen [J]. Drugs Today (Barc), 2001. 4(37): 245-255.
[29] Gursel I, M Gursel. H Yamada et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation[J]. J Immunol. 2003.3(171): 1393-1400.
[30] Hacker H. H Mischak. T Miethke et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation [J]. EMBO J, 1998. 21(17): 6230-6240.
[31] Halpern M D. D S Pisetsky. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers[.I]. Immunopharmacology. 1995. 1(29): 47-52.
[32]Hemmi H,O Takeuchi,T Kawai et al.A Toll-like receptor recognizes bacterial DNA[J].Nature,2000,6813(408):740-745.
[33]Ho P P,P Fontoura,P J Ruiz et al.An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems[J].J Immunol,2003,9(171):4920-4926.
[34]Hochrein H,B Schlatter,M O'Keeffe et al.Herpes simplex virus type-1induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways[J].Proc Natl Acad Sci U S A,2004,31(101):11416-11421.
[35]Honda K,T Taniguchi.IRFs:master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors[J].Nat Rev Immunol,2006,9(6):644-658.
[36]Hu D,X Su,R Sun et al.Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells[J].Mol Immunol,2009.
[37]Iwamura C,T Nakayama.Toll-like receptors in the respiratory system:Their roles in inflammation[J].Current Allergy and Asthma Reports,2008,1(8):7-13.
[38]Janssens S,R Beyaert.Role of Toll-like receptors in pathogen recognition[J].Clin Microbiol Rev,2003,4(16):637-646.
[39]Jin M S,J O Lee.Ligand Recognition by the Toll-like Receptor Family[J].Animal Cells and Systems,2009,1(13):1-8.
[40]Kawai T,S Akira.TLR signaling[J].Seminars in Immunology,2007,1(19):24-32.
[41]Kawai T,S Akira.The roles of TLRs,RLRs and NLRs in pathogen recognition[J].Int Immunol,2009,4(21):317-337.
[42]Ketikoglou I,S Karatapanis,I Elefsiniotis et al.Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B[J].Eur J Dermatol,2005,2(15):107-109.
[43]Kline J N,A M Krieg.Toll-Like Receptor 9 Activation with CpG Oligodeoxynucleotides for Asthma Therapy[J].Drug News & Perspectives,2008,8(21):434-439.
[44]Krieg A M.CpG DNA:a pathogenic factor in systemic lupus erythematosus?[J].J Clin Immunol,1995a,6(15):284-292.
[45]Krieg A M.Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides[J].Biochimica Et Biophysica Acta-Gene Structure and Expression.1999.1(1489):107-116.
[46]Krieg A M.Development of TLR9 agonists for cancer therapy[J].J Clin Invest,2007a,5(117):1184-1194.
[47]Krieg A M.Toll-like receptor 9(TLR9) agonists in the treatment of cancer[J].Oncogene,2008,2(27):161-167.
[48]Krieg A M,J Vollmer.Toll-like receptors 7,8.and 9:linking innate immunity to autoimmunity[J].Immunol Rev,2007b,220):251-269.
[49]Krieg A M,T Wu.R Weeratna et al.Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs[J].Proc Natl Acad Sci U S A,1998,21(95):12631-12636.
[50]Krieg A M,A K Yi,S Matson et al.CpG motifs in bacterial DNA trigger direct B-cell activation[J].Nature,1995b,6522(374):546-549.
[51]Krug A,G D Luker,W Barchet et al.Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9[J].Blood,2004,4(103):1433-1437.
[52]Krug A,S Rothenfusser,V Hornung et al.Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells[J].Eur J Immunol,2001,7(31):2154-2163.
[53]Krug A,S Rothenfusser,S Selinger et al.CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells[J].J Immunol,2003,7(170):3468-3477.
[54]Latz E,A Schoenemeyer,A Visintin et al.TLR9 signals after translocating from the ER to CpG DNA in the lysosome[J].Nat Immunol,2004,2(5):190-198.
[55]Liew F Y,D Xu,E K Brint et al.Negative regulation of toll-like receptor-mediated immune responses[J].Nat Rev Immunol,2005,6(5):446-458.
[56]Macfarlane D E,L Manzel.Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine,chloroquine,and structurally related compounds[J].J Immunol,1998,3(160):1122-1131.
[57]Mallat Z.Suppressive oligodeoxynucleotides inhibit atherosclerosis[J].J Mol Cell Cardiol,2008,2(45):156-158.
[58]Marshak-Rothstein A,I R Rifkin.Immunologically active autoantigens:the role of toll-like receptors in the development of chronic inflammatory disease[J].Annu Rev Immunol,2007,25):419-441.
[59]Martin D A,K B Elkon.Autoantibodies make a U-turn:the toll hypothesis for autoantibody specificity[J].J Exp Med,2005,11(202):1465-1469.
[60]Means T K,E Latz,F Hayashi et al.Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9[J].J Clin Invest,2005,2(115):407-417.
[61]Megyeri K.W C Au,I Rosztoczy et al.Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways[J].Mol Cell Biol,1995,4(15):2207-2218.
[62]Nakano H.M Yanagita.M D Gunn.CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells[J].J Exp Med.2001,8(194):1171-1178.
[63]Nakano S.S Morimoto.J Suzuki et al.Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus[J].Rheumatology(Oxford),2008,2(47):145-149.
[64]Paterson B M,B E Roberts.E L Kuff.Structural gene identification and mapping bv DNA-mRNA hybrid-arrested cell-free translation[J].Proc Natl Acad Sci U S A,1977.10(74):4370-4374.
[65]Patole P S,D Zecher,R D Pawar et al.G-rich DNA suppresses systemic lupus[J].J Am Soc Nephrol,2005,11(16):3273-3280.
[66]Peterson K S,J F Huang,J Zhu et al.Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli[J].J Clin Invest,2004,12(113):1722-1733.
[67]Pisetsky D S.The role of innate immunity in the induction of autoimmunity[J].Autoimmun Rev,2008,1(8):69-72.
[68]Pisetsky D S,C F Reich.Inhibition of murine macrophage IL-12 production by natural and synthetic DNA[J].Clin Immunol,2000,3(96):198-204.
[69]Ronnblom L,M L Eloranta,G V Alm.Role of natural interferon-alpha producing cells(plasmacytoid dendritic cells) in autoimmunity[J].Autoimmunity,2003,8(36):463-472.
[70]Ronnblom L E,G V Alm,K E Oberg.Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors[J].Ann Intern Med,1991,3(115):178-183.
[71]Ross R.Atherosclerosis is an inflammatory disease[J].Am Heart J,1999,5 Pt 2(138):S419-420.
[72]Salaun B,P Romero,S Lebecque.Toll-like receptors' two-edged sword:when immunity meets apoptosis[J].Eur J Immunol,2007,12(37):3311-3318.
[73]Santer D M,T Yoshio,S Minota et al.Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus[J].J Immunol,2009,2(182):1192-1201.
[74]Sobczak K,N Bangel-Ruland,J Semmler et al.[Antisense oligonucleotides for therapy of cystic fibrosis:Inhibition of sodium absorption mediated by ENaC in nasal epithelial cells.][J].HNO,2009.
[75]Stunz L L,P Lenert,D Peckham et al.Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells[J].Eur J Immunol,2002,5(32):1212-1222.
[76]Takeda K,S Akira.Toll-like receptors in innate immunity[J].Int Immunol,2005b,1(17):1-14.
[77]Takeda K,T Kaisho,S Akira.Toll-like receptors[J].Annual Review of Immunology,2003,21):335-376.
[78]Tokunaga T,H Yamamoto,S Shimada et al.Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG.I.Isolation,physicochemical characterization,and antitumor activity[J].J Natl Cancer Inst,1984,4(72):955-962.
[79]Trieu A,T L Roberts,J A Dunn et al.DNA motifs suppressing TLR9responses[J].Crit Rev Immunol,2006,6(26):527-544.
[80]Uematsu S.S Akira.The role of Toll-like receptors in immune disorders[J].Expert Opinion on Biological Therapy,2006.3(6):203-214.
[81]Uematsu S,S Akira.Toll-like receptor and innate immunity[J].Seikagaku,2007.8(79):769-776.
[82]Verthelyi D,K J Ishii.M Gursel et al.Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs[J].J Immunol. 2001, 4(166): 2372-2377.
[83] Vollmer J, A M Krieg. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists[J]. Adv Drug Deliv Rev, 2009, 3(61): 195-204.
[84] Vollmer J, R Weeratna, P Payette et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immuno stimulatory activities [J]. Eur J Immunol, 2004, 1(34): 251-262.
[85] Wiemann B, C O Starnes. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective [J]. Pharmacol Ther, 1994, 3(64): 529-564.
[86] Yamamoto S, E Kuramoto, S Shimada et al. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG[J]. Jpn J Cancer Res, 1988, 7(79): 866-873.
[87] Yao Y, L Richman, C Morehouse et al. Type I interferon: potential therapeutic target for psoriasis?[J]. PLoS One, 2008, 7(3): e2737.
[88] Zamecnik P C, M L Stephenson. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide [J]. Proc Natl Acad Sci U S A, 1978, 1(75): 280-284.
[89] Zhu F G, C F Reich. D S Pisetsky. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides[J]. J Leukoc Biol, 2002a, 6(72): 1154-1163.
[90] Zhu F G, C F Reich, D S Pisetsky. Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides[J]. J Leukoc Biol. 2002b, 4(71): 686-694.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |